{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastro-esophageal+Cancer&page=13", "query": { "condition": "Gastro-esophageal Cancer", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 472, "total_pages": 48, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastro-esophageal+Cancer&page=14&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastro-esophageal+Cancer&page=12&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-25T23:43:24.845Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Lymphoma", "Advanced Malignant Solid Neoplasm", "Bladder Carcinoma", "Breast Carcinoma", "Cervical Carcinoma", "Colon Carcinoma", "Colorectal Carcinoma", "Endometrial Carcinoma", "Esophageal Carcinoma", "Exocrine Pancreas Carcinoma", "Gastric Carcinoma", "Glioma", "Head and Neck Carcinoma", "Hematopoietic and Lymphoid Cell Neoplasm", "Kidney Carcinoma", "Liver Carcinoma", "Lung Carcinoma", "Lymphoma", "Malignant Uterine Corpus Neoplasm", "Malignant Uterine Neoplasm", "Melanoma", "Multiple Myeloma", "Ovarian Carcinoma", "Prostate Carcinoma", "Rectal Carcinoma", "Recurrent Bladder Carcinoma", "Recurrent Breast Carcinoma", "Recurrent Cervical Carcinoma", "Recurrent Colon Carcinoma", "Recurrent Colorectal Carcinoma", "Recurrent Esophageal Carcinoma", "Recurrent Gastric Carcinoma", "Recurrent Glioma", "Recurrent Head and Neck Carcinoma", "Recurrent Liver Carcinoma", "Recurrent Lung Carcinoma", "Recurrent Lymphoma", "Recurrent Malignant Solid Neoplasm", "Recurrent Malignant Uterine Corpus Neoplasm", "Recurrent Melanoma", "Recurrent Multiple Myeloma", "Recurrent Ovarian Carcinoma", "Recurrent Pancreatic Carcinoma", "Recurrent Prostate Carcinoma", "Recurrent Rectal Carcinoma", "Recurrent Skin Carcinoma", "Recurrent Thyroid Gland Carcinoma", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Multiple Myeloma", "Skin Carcinoma", "Thyroid Gland Carcinoma" ], "interventions": [ { "name": "Adavosertib", "type": "DRUG" }, { "name": "Afatinib", "type": "DRUG" }, { "name": "Afatinib Dimaleate", "type": "DRUG" }, { "name": "Binimetinib", "type": "DRUG" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Capivasertib", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Copanlisib", "type": "DRUG" }, { "name": "Copanlisib Hydrochloride", "type": "DRUG" }, { "name": "Crizotinib", "type": "DRUG" }, { "name": "Cytology Specimen Collection Procedure", "type": "OTHER" }, { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Dabrafenib Mesylate", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Defactinib", "type": "DRUG" }, { "name": "Defactinib Hydrochloride", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Erdafitinib", "type": "DRUG" }, { "name": "Fexagratinib", "type": "DRUG" }, { "name": "Ipatasertib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Larotrectinib", "type": "DRUG" }, { "name": "Larotrectinib Sulfate", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Osimertinib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Pertuzumab", "type": "BIOLOGICAL" }, { "name": "PI3K-beta Inhibitor GSK2636771", "type": "DRUG" }, { "name": "Radiologic Examination", "type": "PROCEDURE" }, { "name": "Radionuclide Imaging", "type": "PROCEDURE" }, { "name": "Relatlimab", "type": "BIOLOGICAL" }, { "name": "Sapanisertib", "type": "DRUG" }, { "name": "Sunitinib Malate", "type": "DRUG" }, { "name": "Taselisib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Trastuzumab Emtansine", "type": "BIOLOGICAL" }, { "name": "Ulixertinib", "type": "DRUG" }, { "name": "Vismodegib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6452, "start_date": "2015-08-17", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-10-22", "last_synced_at": "2026-10-25T23:43:24.845Z", "location_count": 1405, "location_summary": "Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 847 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fairhope", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02465060" }, { "nct_id": "NCT00582647", "title": "Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Esophageal Cancer", "Bile Duct Neoplasms", "Gastric Cancer", "Liver Cancer", "Melanoma", "Pancreatic Cancer", "Sarcoma" ], "interventions": [], "intervention_types": [], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6000, "start_date": "2000-03", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-01-15", "last_synced_at": "2026-10-25T23:43:24.845Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00582647" }, { "nct_id": "NCT03642093", "title": "HOPE - A Study to Evaluate the Effect of a Prehabilitation Program on GI Cancer Patients Planning to Undergo Surgery", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pancreatic Cancer", "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "Nutritional Intervention", "type": "COMBINATION_PRODUCT" }, { "name": "Physical Activity Intervention", "type": "BEHAVIORAL" } ], "intervention_types": [ "COMBINATION_PRODUCT", "BEHAVIORAL" ], "sponsor": "Siobhan Trotter", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "25 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "25 Years to 80 Years" }, "enrollment_count": 60, "start_date": "2018-08-01", "completion_date": "2019-05", "has_results": false, "last_update_posted_date": "2018-09-11", "last_synced_at": "2026-10-25T23:43:24.845Z", "location_count": 1, "location_summary": "New Orleans, Louisiana", "locations": [ { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03642093" }, { "nct_id": "NCT03611309", "title": "Perioperative Palliative Care Surrounding Cancer Surgery for Patients & Their Family Members", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Gastrointestinal Cancer" ], "interventions": [ { "name": "Surgeon-palliative care team co management", "type": "OTHER" }, { "name": "Surgeon team alone management", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 379, "start_date": "2018-09-25", "completion_date": "2022-08-31", "has_results": true, "last_update_posted_date": "2026-01-08", "last_synced_at": "2026-10-25T23:43:24.845Z", "location_count": 5, "location_summary": "Stanford, California • Baltimore, Maryland • Boston, Massachusetts + 2 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03611309" }, { "nct_id": "NCT02970539", "title": "Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastric Cancer", "Esophageal Cancer", "Gastro-esophageal Cancer" ], "interventions": [ { "name": "Oraxol", "type": "DRUG" }, { "name": "Ramucirumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Athenex, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2016-12-08", "completion_date": "2022-12-31", "has_results": false, "last_update_posted_date": "2022-02-16", "last_synced_at": "2026-10-25T23:43:24.845Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02970539" }, { "nct_id": "NCT06943521", "title": "A Study of MT-4561 in Patients With Various Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma (HNSCC)", "Non-small Cell Lung Cancer (NSCLC)", "Esophageal Cancer", "Gastric Cancer", "Biliary Tract Cancer", "Pancreatic Ductal Adenocarcinoma (PDAC)", "Breast Cancer", "Ovarian Cancer", "Cervical Cancer", "Endometrial Cancer", "Prostate Cancer", "Urothelial Carcinoma", "Neuroendocrine Tumor (NET)", "Neuroendocrine Carcinoma (NEC)", "Soft Tissue Sarcoma", "Nuclear Protein in Testis (NUT) Carcinoma" ], "interventions": [ { "name": "MT-4561", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tanabe Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2025-04-18", "completion_date": "2028-08", "has_results": false, "last_update_posted_date": "2025-12-11", "last_synced_at": "2026-10-25T23:43:24.845Z", "location_count": 4, "location_summary": "Los Angeles, California • Grand Rapids, Michigan • Columbus, Ohio + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06943521" }, { "nct_id": "NCT06266299", "title": "A Study of KK2269 in Adult Participants With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Metastatic Solid Tumor", "Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Esophageal Adenocarcinoma", "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "KK2269", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kyowa Kirin Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 101, "start_date": "2024-01-18", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-10-25T23:43:24.845Z", "location_count": 7, "location_summary": "Scottsdale, Arizona • Duarte, California • Newport Beach, California + 4 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT06266299" }, { "nct_id": "NCT06824363", "title": "ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Solid Tumor, Adult", "Malignant Solid Tumor", "Stomach Adenocarcinoma", "Esophageal Adenocarcinoma" ], "interventions": [ { "name": "Tremelimumab", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Irvine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2026-05-25", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-10-25T23:43:24.845Z", "location_count": 1, "location_summary": "Orange, California", "locations": [ { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06824363" }, { "nct_id": "NCT03342937", "title": "KeyLargo: Pembrolizumab + Oxaliplatin + Capecitabine in Gastric Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Cancer", "Esophagus Cancer" ], "interventions": [ { "name": "Oxaliplatin+Capecitabine+Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2018-01-11", "completion_date": "2023-02-06", "has_results": true, "last_update_posted_date": "2024-03-13", "last_synced_at": "2026-10-25T23:43:24.845Z", "location_count": 7, "location_summary": "Clayton, North Carolina • Durham, North Carolina • Henderson, North Carolina + 4 more", "locations": [ { "city": "Clayton", "state": "North Carolina" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Henderson", "state": "North Carolina" }, { "city": "Laurinburg", "state": "North Carolina" }, { "city": "Lumberton", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03342937" }, { "nct_id": "NCT06695845", "title": "A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Gastric Cancer", "Esophageal Cancer", "Gastroesophageal Cancer", "Colorectal Cancer", "Endometrial Cancer", "Non-small Cell Lung Cancer", "Ovarian Cancer", "Urothelial Carcinoma", "Salivary Gland Cancer", "Pancreatic Cancer", "HER-2 Protein Overexpression" ], "interventions": [ { "name": "Zanidatamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jazz Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2025-01-14", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-10-25T23:43:24.845Z", "location_count": 17, "location_summary": "Prescott, Arizona • Littleton, Colorado • Fort Myers, Florida + 14 more", "locations": [ { "city": "Prescott", "state": "Arizona" }, { "city": "Littleton", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06695845" } ] }